Consistent with our analysis, the expression level of TGM3 is high in hepatocellular carcinoma but low in other epithelial carcinomas, such as laryngeal carcinoma and esophageal carcinoma (Chen et al., 2000; He et al., 2002; Li et al., 2016b; Hu et al., 2020), Kaplan–Meier survival analysis showed that high TGM3 expression signified a poor prognosis for patients suffering from most cancers, except PAAD, which indicated a clear association of TGM3 expression with cancer survival and prognosis, suggesting that TGM3 is a potential biomarker for cancer monitoring. The gene discussed is TGM3; the disease is cancer.